Ποια είναι η τιμή για GlycoNex Incorporation (4168)

Η τιμή για GlycoNex Incorporation (4168) είναι $0.71865803

Ποια είναι η κεφαλαιοποίηση αγοράς για GlycoNex Incorporation (4168)

Η κεφαλαιοποίηση αγοράς για GlycoNex Incorporation (4168) είναι $80.86M

GlycoNex Incorporation (4168) Τιμή και Κεφαλαιοποίηση Αγοράς

GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.

Η τιμή για 4168	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$46,314.83 $80.86M	NVDA	$5.211T	+6,444,526.45%
$40,408.14 $80.86M	AAPL	$4.547T	+5,622,622.18%
$36,993.03 $80.86M	GOOG	$4.162T	+5,147,415.61%
$31,930.09 $80.86M	MSFT	$3.593T	+4,442,915.76%
$24,820.84 $80.86M	AMZN	$2.793T	+3,453,676.39%

Η τιμή για 4168

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$46,314.83 $80.86M